[SUBJECT]


	MEDICAL NEWS SITES


			BioSpace Single Use Bronchoscopes Market: Increased number of lung cancer cases across the globe is foreseen to boost the market demand

	Global Single Use Bronchoscopes Market: Snapshot Increase in people living with various critical respiratory health conditions is foreseen to boost demand avenues in the global single use bronchoscopes market from 2020 to 2030. Bronchoscopy refers to interventional pulmonology procedures carried out with the help of bronchoscope. The process of bronchoscopy can be performed using single use bronchoscopes or reusable bronchoscopes. An upcoming research report by Transparency Market Research on the single use bronchoscopes market provides deep insights on key factors showing positive or negative impact on overall market growth. Read more


			MedScape Cooperative Group Research Endeavors in Small-Cell Lung Cancer

	The EORTC extends over multiple European countries and is a key contributor to clinical lung cancer research. Building upon the Intergroup 0096 study in LS-SCLC, the CONVERT (Concurrent ONce-daily VErsus Radiotherapy Twice-daily) trial hypothesizes that increasing the total dose of once-daily thoracic irradiation will improve efficacy and negate the benefit of twice-daily fractionation, thus making the once-daily regimen more practical and logistically easier to deliver. The CONVERT trial is a 2-arm, multicenter, randomized phase III Intergroup trial comparing a once-daily with a twice-daily schedule, given concurrently with cisplatin and etoposide (Figure 2). Read more


			MedScape Natural History of Stage I Non-Small Cell Lung Cancer: Implications

	Data were obtained on 101,844 incident non-small cell lung cancer (NSCLC) cases in the CCR during the period from 1989 to 2003 with TNM staging data and complete follow-up data available. This included 19,702 stage I, 3,753 stage II, 10,429 stage IIIA, 22,285 stage IIIB, and 45,675 stage IV NSCLC patients. Recorded data included demographic information (age, gender, ethnicity), stage at presentation, histology, tumor size, tumor location, socioeconomic status, and vital status. Socioeconomic status is denoted as a single-index variable in CCR using statewide measures of education, income, and occupation as described previously.[9] Data were abstracted from medical and laboratory records by trained tumor registrars according to the Californi... Read more


			MedScape Genomic Prognostic Models in Early-Stage Lung Cancer

	Despite our best efforts, little effect on the survival of patients diagnosed with lung cancer has been made in the past 30 years. Even patients with early-stage lung cancer demonstrate significant recurrence rates and lower-than-expected survival rates after surgical resection. The development of genomic prognostic models holds significant promise in our ability to differentiate among those patients who might benefit from additional therapy or lesser surgical procedures. An effort to move forward with developing a robust prognostic genomic model for use in the clinical setting should be prompted by encouraging results obtained in the field of breast oncology. Read more


			MedScape Third- and Further-line Therapy in Advanced NSCLC Patients

	Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical characteristics and histological and biological features of the disease. In nonsquamous NSCLC, novel agents, such as pemetrexed and bevacizumab, have improved survival in the first-line setting. Maintenance therapy with pemetrexed and erlotinib resulted in improved progression-free survival compared with second-line therapy at disease progression. Read more


			Targeted Oncology CASPIAN Trial Results Offer Another Option for SCLC

	The results from the phase 3 CASPIAN trial were reviewed and compared with the phase 3 IMpower133 by Jyoti D. Patel, MD, professor of Medicine, (Hematology and Oncology), and associate vice chair for Clinical Research at Northwestern University in Chicago, IL during a Targeted Oncology Case Based Peer Perspectives event. Targeted Oncology™: What do the National Comprehensive Cancer Network (NCCN) guidelines suggest in this setting? PATEL: Atezolizumab [Tecentriq] has been approved, [and] now durvalumab [Imfinzi] has been approved.1 With durvalumab, you have the option of using either carboplatin or cisplatin. Read more


			MedScape Medscape \| Expert Rev Anticancer Ther - Publication Information

	A Therapeutic Target for the Management of Chronic-Phase Chronic Myeloid Leukemia Learn more about the pathobiology of CML and explore emerging strategies to optimize chronic-phase CML management. Lymph Node-Positive Bladder Cancer Lymphatic metastasis is associated with markedly worse prognosis in patients with bladder cancer, although surgical resection and chemotherapy can still provide long-term survival for selected patients. Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations Non-small-cell lung cancer may be the leading cause of cancer-related deaths, but new targeted therapies may change that. Read more


	JOURNALS


			The Lancet Pre-treatment optimization with pulmonary rehabilitation in lung cancer: Making the inoperable patients operable

	Background Anatomical lung resection offers the best prospect of long-term survival in patients with non-small cell lung cancer (NSCLC). However, some patients with significant dyspnoea, impaired performance status (PS), borderline or poor pulmonary function are considered inoperable and instead referred for radiotherapy, chemotherapy or palliative care. The aims of the study were to determine whether pre-operative pulmonary physiotherapy (Prehab), by improving clinical parameters, (i) makes patients suitable for surgery who were considered inoperable on subjective criteria of dyspnoea >3 and PS >2, and objective criteria of diffusing capacity for carbon monoxide (DLCO) <50%; and (ii) thereby allows them to safely receive curative surgery w... Read more


			Dove Press Distinct Proteins in Protein Corona of Nanoparticles Represent a Promi \| IJN

	Nanocarriers, in general, preferentially accumulate in tumor tissues by the enhanced permeability and retention (EPR) effect. The tumor possesses a leaky vasculature, which allows the extravasation of NPs from the blood capillaries. In addition, it lacks lymphatic drainage allowing the drug-loaded NPs to reside at the tumor site for a longer duration compared to the free drug molecules. However, overreliance on passive targeting is sometimes misleading; EPR effect is a heterogeneous phenomenon that is not a universal property of all types of cancer.1–4 Passive targeting can improve the contact probability between the NPs and the target cells; however, it does not affect the intracellular uptake of the NPs which is largely dependent on the c... Read more


			Dove Press Characterization of Stable and Reactive Metabolites of the Anticancer \| DDDT

	Cancer is the second leading cause of death worldwide and is accountable for about 9.6 million casualties in 2018, with almost one-sixth of global deaths.1 Earlier studies have shown that molecular-targeted therapeutic approaches were successful in treating cancer cases by targeting genes, oncogenes, and tumor suppressors involved in cancer progression.2 Lung cancer has the highest mortality rate globally among all cancer types. In 2012, 1.59 million deaths were attributed to lung cancer, which is 20% of all cancer deaths.3 Non-small-cell lung cancers (NSCLCs) account for 90% of all lung cancer cases and have various subtypes that are triggered by several activated oncogenes.4,5 The treatment of patients with NSCLC was greatly improved by a... Read more


			Springer First steps in PROMs and PREMs collection in Wales as part of the prudent and value-based healthcare agenda

	Here, we present the results of our work to develop an electronic platform which uses recognised tools to collect patient-reported data in a form which facilitates both individual patient-level use and cohort analysis. A fully integrated national electronic data collection platform has been successfully deployed for use in HBs and Trusts in Wales with the first data collected in June 2016. Uptake across HBs has varied as different clinical areas have implemented use at their own pace, with some organisations choosing to use alternative systems to meet specific needs. Read more


	FINANCE SITES


			Yahoo Finance Britain expects "very significant" week for Brexit talks as clock ticks down

	TipRanks Following the wild ride that was 2020, where does the market go from here? Major strides have been made in the COVID-19 vaccine race, yet the near-term picture remains unclear, blurred by the virus’ resurgence and the stimulus stalemate on Capitol Hill.In times like these, the investing greats can serve as a source of inspiration, namely billionaire Israel “Izzy” Englander.Who exactly is Englander? The legend, who started trading stocks when he was in high school, began his career interning at investment firm Oppenheimer, later going on to purchase a seat on the American Stock Exchange, where he would serve as a floor broker, trader and specialist.In 1989, along with Ronald Shear, Englander founded hedge fund Millennium Management. Read more


			Yahoo Finance UK's Raab: There is a risk of third coronavirus wave

	TipRanks Following the wild ride that was 2020, where does the market go from here? Major strides have been made in the COVID-19 vaccine race, yet the near-term picture remains unclear, blurred by the virus’ resurgence and the stimulus stalemate on Capitol Hill.In times like these, the investing greats can serve as a source of inspiration, namely billionaire Israel “Izzy” Englander.Who exactly is Englander? The legend, who started trading stocks when he was in high school, began his career interning at investment firm Oppenheimer, later going on to purchase a seat on the American Stock Exchange, where he would serve as a floor broker, trader and specialist.In 1989, along with Ronald Shear, Englander founded hedge fund Millennium Management. Read more


			Yahoo Finance Top 10 Healthcare Stocks To Buy for the Future

	In this article we present the list of Top 10 Healthcare Stocks To Buy for the Future. Click to skip ahead and see the Top 5 Healthcare Stocks for the Future. Small- and mid-cap biotech and pharmaceutical companies represent some of the most compelling gambles available on the market. All it takes is one blockbuster drug to be developed for a small-cap biotech’s shares to explode by dizzying multiples. One need only look to a company like Questcor Pharmaceuticals, which rode a single drug, Acthar, to greater than 5,000% gains and eventually a sale to Mallinckrodt PLC (OTCMKTS:MNKKQ) for $5.6 billion. On the other hand, there are an untold number of pharma companies that held once-promising pipelines that ended up fizzling out into nothing, ... Read more


			Yahoo Finance Fresno St. men's basketball program to quarantine after positive COVID-19 tests

	TipRanks Following the wild ride that was 2020, where does the market go from here? Major strides have been made in the COVID-19 vaccine race, yet the near-term picture remains unclear, blurred by the virus’ resurgence and the stimulus stalemate on Capitol Hill.In times like these, the investing greats can serve as a source of inspiration, namely billionaire Israel “Izzy” Englander.Who exactly is Englander? The legend, who started trading stocks when he was in high school, began his career interning at investment firm Oppenheimer, later going on to purchase a seat on the American Stock Exchange, where he would serve as a floor broker, trader and specialist.In 1989, along with Ronald Shear, Englander founded hedge fund Millennium Management. Read more


	SOCIAL MEDIA


			Twitter OncLive.com ICYMI, lcsm: 29/11/2020 16:01:10

	#ICYMI: @US_FDA Approves First Companion Diagnostic for Expanded EGFR TKIs in NSCLC #lcsm Read more


			Twitter OncLive.com : 29/11/2020 18:00:40

	Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and toxicity profiles should guide treatment decisions. @PatelOncology @UCSD Read more


			Twitter Targeted Oncology liquidbiopsy: 30/11/2020 03:00:31

	Target capture next-generation sequencing, MassARRAY, and real-time quantitative polymerase chain reaction all effectively detected low frequency somatic epidermal growth factor receptor mutations in cell-free ctDNA from patients with NSCLC. Read more


			Twitter SeqComplete DNAsequencing, ngs, genomics: 30/11/2020 05:37:12

	#DNAsequencing #ngs #genomics Low-Level EGFR Variants in NSCLC Detectable by Liquid Biopsy Assays \| Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways https://t.co/iplqaJ7zwj, see more Read more